Takeda Pharmaceutical's Third-Quarter Net Profit Dropped on Lower Margins
By Kosaku Narioka
Takeda Pharmaceutical reported a drop in its third-quarter net profit due partly to lower margins despite some growth in revenue.
The Japanese drugmaker said Thursday that net profit decreased 11% from a year earlier to 105.7 billion yen ($719.3 million) for the three months ended Dec. 31. That beat the estimate of Y78.165 billion in a poll of analysts by data provider Quick.
Third-quarter revenue increased 1.3% from a year earlier to Y1.111 trillion even as Takeda lost U.S. market exclusivity for Vyvanse, a blockbuster drug for attention deficit hyperactivity disorder, in late August.
Sales of Vyvanse fell 30% to Y86.6 billion, while sales of ulcerative colitis drug Entyvio climbed 13% to Y227.6 billion and sales of plasma-derived products rose 18% to Y222.8 billion.
Third-quarter operating profit margin deteriorated to 9.4% from 13.4% a year earlier due partly to higher costs of sales and research and development expenses.
Takeda Pharmaceutical kept its revenue and net-profit forecasts unchanged for the fiscal year ending March. It continues to expect net profit to drop 71% to Y93.00 billion and revenue to decline 1.2% to Y3.980 trillion.
Write to Kosaku Narioka at kosaku.narioka@wsj.com
(END) Dow Jones Newswires
February 01, 2024 01:55 ET (06:55 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks